Compagnie Lombard Odier SCmA trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 213,907 shares of the biopharmaceutical company’s stock after selling 49,258 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Gilead Sciences were worth $15,138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the stock. First Allied Advisory Services Inc. grew its position in Gilead Sciences by 13.0% during the 2nd quarter. First Allied Advisory Services Inc. now owns 102,994 shares of the biopharmaceutical company’s stock valued at $7,287,000 after purchasing an additional 11,824 shares during the last quarter. Graham Capital Management L.P. purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $1,175,000. PDT Partners LLC grew its position in Gilead Sciences by 93.4% during the 2nd quarter. PDT Partners LLC now owns 177,200 shares of the biopharmaceutical company’s stock valued at $12,542,000 after purchasing an additional 85,577 shares during the last quarter. Arete Wealth Advisors LLC grew its position in Gilead Sciences by 13.1% during the 2nd quarter. Arete Wealth Advisors LLC now owns 9,416 shares of the biopharmaceutical company’s stock valued at $666,000 after purchasing an additional 1,093 shares during the last quarter. Finally, Frontier Wealth Management LLC grew its position in Gilead Sciences by 10.7% during the 2nd quarter. Frontier Wealth Management LLC now owns 133,631 shares of the biopharmaceutical company’s stock valued at $9,458,000 after purchasing an additional 12,870 shares during the last quarter. Institutional investors own 76.23% of the company’s stock.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last three months, insiders sold 546,819 shares of company stock worth $41,808,839. 1.30% of the stock is currently owned by insiders.
Gilead Sciences, Inc. (GILD) opened at $73.29 on Wednesday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market cap of $95,475.20, a P/E ratio of 7.63, a P/E/G ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.75 earnings per share. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/06/compagnie-lombard-odier-scma-decreases-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.